Using the Angiogenesis Inhibitor Pazopanib to Treat Ovarian Cancer
Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses a phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses a randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Pazopanib is an oral drug that blocks several targets involved in angiogenesis. In the trial, the median time to progression-free survival in the pazopanib arm was 17.9 months compared to 12.3 months for placebo. This trial provides further evidence that angiogenesis is an important target in the treatment of patients with ovarian cancer, Aghajanian notes.
- A phase III randomized trial compared the oral targeted drug pazopanib to placebo in ovarian cancer
- The median time to progression-free survival in the pazopanib arm was 17.9 months compared to 12.3 months for placebo
- This trial provides further evidence that angiogenesis is an important target in the treatment of patients with ovarian cancer, Aghajanian notes
<<<
Avutometinib/Defactinib Leads to Positive Response, Survival Data in Ovarian Cancer
October 18th 2024The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is expected to be finalized with the FDA by the end of the month.
Read More
